KRTAP19-1: A Potential Drug Target and Biomarker (G337882)

Target Name: KRTAP19-1

NCBI ID: G337882

KRTAP19-1

KRTAP19-1: A Potential Drug Target and Biomarker

Keratin-associated protein 19-1 (KRTAP19-1) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization make it an attractive target for small molecules and antibodies. In this article, we will explore the biology of KRTAP19-1, its potential drug target properties, and its potential as a biomarker.

Structure and Localization

KRTAP19-1 is a 21-kDa protein that is expressed in most tissues and cells in the body. It is primarily localized to the cytoplasm and the endoplasmic reticulum (ER), and is also found in the peroxisome and the mitochondria. KRTAP19-1 has a unique structure, with a long amino acid tail that is involved in its localization to different cellular compartments.

KRTAP19-1 functions as a negative regulator of the T-cell receptor (TCR), which is a critical protein that plays a central role in immune surveillance. The TCR is a transmembrane protein that consists of a variable region and a constant region. The variable region is involved in the recognition of antigens, while the constant region is involved in the regulation of the T-cell response.

KRTAP19-1 is known to be a negative regulator of the TCR, which means that it prevents the TCR from functioning. This regulation is critical for the survival of T cells, as T-cell exhaustion is a major risk factor for cancer and other chronic diseases.

Potential Drug Target

KRTAP19-1 is a potential drug target due to its unique structure and subcellular localization. Its long amino acid tail makes it a potential target for small molecules that can interact with the tail and disrupt its function. Additionally, KRTAP19-1 is a protein that is expressed in most tissues and cells in the body, which makes it a potential biomarker for drug responses.

In addition to its potential as a drug target, KRTAP19-1 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, KRTAP19-1 has been shown to be downregulated in several types of cancer, including breast, ovarian, and prostate cancer. This suggests that targeting KRTAP19-1 may be an effective way to treat these cancers.

In addition to its potential as a drug target and biomarker, KRTAP19-1 is also a potential target for therapeutic antibodies. The unique structure of KRTAP19-1 makes it a potential candidate for antibodies that can interact with the protein and disrupt its function.

Conclusion

In conclusion, KRTAP19-1 is a protein that has been identified as a potential drug target and biomarker for several diseases. Its unique structure and subcellular localization make it an attractive target for small molecules and antibodies. Additionally, its function as a negative regulator of the T-cell receptor makes it a potential target for drugs that can disrupt its function. Further research is needed to fully understand the biology of KRTAP19-1 and its potential as a drug target and biomarker.

Protein Name: Keratin Associated Protein 19-1

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP19-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP19-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets